MDACC Study No:2006-0935 ( NCT No: NCT00652574)
Title:Phase I Trial of Induction Dasatinib Therapy in Patients with Resectable Malignant Pleural Mesothelioma
Principal Investigator:Anne S. Tsao
Treatment Agent:Dasatinib
Study Status:Closed
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase I
Treatment Agents:Dasatinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Surgery following 28 days of dasatinib treatment
Supported By:Bristol-Myers Squibb
U.S. Department of Defense
Return Visit:Weekly during the first 4 weeks.
Home Care:Dasatinib tablets will be taken at home. Tablets should not be crushed or cut;
they should be swallowed whole. Patient will be given 28 days of dasatinib
therapy (70 mg po BID) for the duration of this trial.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Anne S. Tsao
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults